COHERUS ONCOLOGY INC

CHRS is the ticker symbol for Coherus BioSciences, Inc., a commercial-stage biopharmaceutical company. The stock represents ownership in a business focused on developing, manufacturing, and commercializing biologic medicines, including biosimilars and immuno-oncology therapies. CHRS trades on the Nasdaq Global Select Market. As with any stock, its value reflects investor expectations about the company's future earnings, product pipeline, and competitive position in the pharmaceutical sector.

Recent performance for CHRS depends on daily market activity and company-specific news. For the latest price changes, percentage moves, and volume, please refer to the real-time quote and performance chart displayed on this page. Those figures reflect the most current trading data available. Historical price trends can also be reviewed to understand how the stock has behaved over different time frames, but past results do not guarantee future outcomes.

The 52-week range shows the lowest and highest prices at which CHRS has traded over the past year. This range can help investors gauge recent price volatility and where the current price sits relative to its annual low and high. For the exact figures, check the up-to-date 52-week range provided on this page, as these values change with market activity.

Evaluating CHRS valuation involves reviewing metrics such as price-to-sales, price-to-earnings (if applicable), and enterprise value relative to revenue or pipeline potential. Because Coherus BioSciences is a biopharmaceutical company, analysts often consider product revenue growth, research and development spending, and the outlook for its drug candidates. Comparing these metrics with peers in the biotechnology sector can provide context. Current valuation ratios are available on this page.

CHRS does not currently pay a regular dividend. As a commercial-stage biopharmaceutical company, Coherus BioSciences typically reinvests cash into research, development, and commercialization of its product portfolio rather than distributing profits to shareholders. For the most up-to-date dividend information, including any special distributions, please refer to the dividend section on this page.

Key risks for CHRS include clinical trial failures, regulatory setbacks, competition from other biologics and biosimilars, manufacturing challenges, and dependence on a limited number of products for revenue. Intellectual property disputes and pricing pressure in the pharmaceutical industry can also affect results. Additionally, as a smaller-cap biopharma stock, CHRS may experience higher price volatility than larger, diversified healthcare companies.